Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration

NCT04047472 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

397

Enrollment

INDUSTRY

Sponsor class

Conditions

Neovascular Age-Related Macular Degeneration

Interventions

DRUG: Brolucizumab 6mg
DRUG: Aflibercept 2 mg

Sponsor

Novartis Pharmaceuticals